Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Phase I And Pharmacokinetic Study Of Ecteinascidin-743, A New Marine Compound, Administered As A 24-hour Continuous Infusion In Patients With Solid Tumors.

A. Taamma, J. Misset, M. Riofrío, C. Guzmán, E. Brain, L. López Lázaro, H. Rosing, J. Jimeno, E. Cvitkovic
Published 2001 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
PURPOSE To define the maximum-tolerated dose (MTD) and the phase II recommended dose (RD) of ecteinascidin-743 (ET-743) given as a 24-hour continuous infusion every 3 weeks to patients with treatment-refractory solid tumors. PATIENTS AND METHODS Fifty-two patients received a total of 158 cycles of ET-743 at one of nine dose levels (DLs) ranging from 50 to 1,800 microg/m(2). RESULTS The MTD was defined as 1,800 microg/m(2) (DL 9), and the phase II RD was 1,500 microg/m(2) (DL 8) for moderately pretreated patients with performance status (PS) 0 to 1 and good hepatobiliary function. Neutropenia and thrombocytopenia were the dose-limiting toxicities (DLTs) and were severe at the MTD (1,800 microg/m(2)) in 94% and 25% of cycles, respectively. At the RD (1,500 microg/m(2)), neutropenia and thrombocytopenia were present in 33% and 10% of cycles, respectively. Transient acute elevated transaminase levels occurred in almost all cycles and was severe in 38% of cycles. Severe toxicities and DLTs were observed in patients with poor PS or abnormal liver function or who had received a large number of previous chemotherapy regimens. Antitumor activity was observed at the three highest DLs, including three partial responses (breast cancer, osteosarcoma, and liposarcoma), and four patients (all with progressing soft tissue sarcomas) had stable disease lasting > or = 3 months. Pharmacokinetic studies were performed on all patients for at least the first cycle, giving a linear pharmacokinetic profile; this showed a relationship between area under the curve (AUC) and transaminitis grade and a clear correlation between AUC and severe hematologic toxicity likelihood. CONCLUSION The RD for a 24-hour continuous intravenous infusion of ET-743 is 1,500 microg/m(2), with the most prevalent DLTs being hematologic. Patients with minor baseline hepatobiliary function abnormalities have a higher likelihood of severe hematologic toxicities and AUC-related DLTs, requiring dose adjustments or delays.
This paper references
10.1200/JCO.2000.18.3.562
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.
J. Alexandre (2000)
10.1073/PNAS.97.12.6775
Ecteinascidin 743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation.
S. Jin (2000)
10.1200/JCO.1997.15.1.251
Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.
P. Rougier (1997)
10.1023/A:1008273402204
Frey's syndrome after cisplatin-based chemotherapy for testicular teratoma.
P. Beale (1998)
10.1021/BI960306B
DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata.
Y. Pommier (1996)
10.1200/JCO.1995.13.11.2688
Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
L. Gianni (1995)
The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma.
V. Bramwell (1997)
10.1054/bjoc.2000.1224
Isolation and characterization of an IGROV-1 human ovarian cancer cell line made resistant to Ecteinascidin-743 (ET-743)
E. Erba (2000)
Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts.
G. Valoti (1998)
10.1002/(SICI)1096-9888(1998110)33:11<1134::AID-JMS730>3.0.CO;2-S
Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
H. Rosing (1998)
10.1056/NEJM199810013391407
Treatment of breast cancer.
G. Hortobagyi (1998)
10.1023/A:1008356726147
Hepatic toxicity from cyclophosphamide, methotrexate, fluorouracil (CMF regimen)
M. Locatelli (1999)
10.1200/JCO.2001.19.5.1248
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity.
S. Delaloge (2001)
10.1023/A:1008364727071
High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.
H. Hendriks (1999)
10.1023/A:1008430827281
In vitro schedule-dependency of myelotoxicity and cytotoxicity of Ecteinascidin 743 (ET-743).
M. Ghielmini (1998)
10.1021/JA9704500
NMR-BASED MODEL OF AN ECTEINASCIDIN 743-DNA ADDUCT
B. Moore (1997)
10.1200/JCO.1996.14.4.1128
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
M. Rothenberg (1996)
10.1200/JCO.1995.13.12.2886
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.
V. Valero (1995)
10.1038/bjc.1998.421
Mature results from three large controlled studies with raltitrexed ('Tomudex').
D. Cunningham (1998)
10.1358/DOF.1996.021.11.385487
PROGRESS IN THE ACQUISITION OF NEW MARINE-DERIVED ANTICANCER COMPOUNDS : DEVELOPMENT OF ECTEINASCIDIN-743 (ET-743)
J. Jimeno (1996)
Molecular and crystal structures of ecteinascidins: potent antitumor compounds from the Caribbean tunicate Ecteinascidia turbinata.
Y. Guan (1993)
10.1023/A:1008224322396
In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
E. Izbicka (1998)



This paper is referenced by
10.2147/TCRM.S1174
Trabectedin and its potential in the treatment of soft tissue sarcoma
P. Cassier (2008)
10.1634/THEONCOLOGIST.7-SUPPL_3-34
Cytotoxic agents in the era of molecular targets and genomics.
B. Chabner (2002)
10.1002/cncr.32117
Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma
S. Patel (2019)
10.1080/14656566.2016.1204295
Trabectedin for the treatment of soft tissue sarcomas
R. De Sanctis (2016)
A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study.
Loretta Lau (2005)
10.1038/sj.clpt.6100259
Mechanism‐based Pharmacokinetic/Pharmacodynamic Meta‐analysis of Trabectedin (ET‐743, Yondelis) Induced Neutropenia
J. Hing (2008)
10.1586/era.10.59
Trabectedin combined with liposomal doxorubicin in women with relapsed ovarian cancer
J. M. Del Campo (2010)
Overcoming multidrug drug resistance in P-glycoprotein/MDR1-overexpressing cell lines by ecteinascidin 743.
A. Kanzaki (2002)
10.1016/j.ejca.2004.09.005
Marine pharmacology in 2001-2: antitumour and cytotoxic compounds.
A. M. Mayer (2004)
10.5114/WO.2011.26437
Trabectedin in patients with pre-treated advanced soft tissue sarcoma: a retrospective single center analysis
Hanna Koseła (2011)
10.1081/cnv-200051387
Abstracts
(2005)
Rat and human liver cytochrome P-450 isoform metabolism of ecteinascidin 743 does not predict gender-dependent toxicity in humans.
J. Reid (2002)
10.1007/s10269-007-0785-z
Les alkylants
F. Ben Abid (2007)
10.3389/fchem.2014.00020
Cancer wars: natural products strike back
Christine Basmadjian (2014)
10.1586/17512433.2016.1152179
Treatment of advanced soft tissue sarcoma: efficacy and safety of trabectedin, a multitarget agent, and update on other systemic therapeutic options
F. Duffaud (2016)
10.2217/imt-2017-0046
PM01183 inhibits myeloid-derived suppressor cells in vitro and in vivo.
Hiromasa Kuroda (2017)
Role of hepatic transport proteins in drug disposition and drug-induced liver injury
Jin Kyung Lee (2009)
10.1016/J.PHRS.2004.12.001
Hepatotoxicity and metabolism of trabectedin: a literature review.
J. Beumer (2005)
10.4137/CMRO.S1605
Management of Ovarian Cancer and Soft Tissue Sarcoma: Focus on Trabectedin
K. Dahl (2011)
10.1023/A:1023577514605
Pharmacokinetic–pharmacodynamic Guided Trial Design in Oncology
Ch. van Kesteren (2004)
10.1007/978-1-59745-221-2_20
Topoisomerase I Poisons and Apoptotic Topoisomerase I-DNA Complexes
O. Sordet (2007)
O PAPEL DA TRABECTEDINA NOS SARCOMAS
Sarah Filipa Carvalho Lopes (2015)
10.1002/cncr.11563
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
C. Laverdière (2003)
10.1016/j.bmcl.2008.02.040
1-Aryl-tetrahydroisoquinoline analogs as active anti-HIV agents in vitro.
P. Cheng (2008)
10.1517/17425255.2012.636353
Clinical and pharmacokinetic evaluation of trabectedin for the treatment of soft-tissue sarcoma
A. Cioffi (2012)
10.2217/14796694.3.4.381
Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
P. Schöffski (2007)
10.1002/cncr.33120
Pharmacokinetics, safety, and activity of trabectedin as first‐line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group
F. Grosso (2020)
New therapeutics for soft-tissue sarcomas in adults.
M. von Mehren (2007)
10.1016/j.suc.2008.03.004
Chemotherapeutic management of soft tissue sarcoma.
K. Thornton (2008)
10.1007/s10637-010-9561-9
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasone
L. Paz-Ares (2010)
10.1007/s40610-019-00125-9
Novel Drug Treatments for Ewing Sarcoma
Reiya Hayden (2019)
10.1517/13543784.12.11.1843
Preclinical and clinical results with the natural marine product ET-743
M. D'Incalci (2003)
See more
Semantic Scholar Logo Some data provided by SemanticScholar